Review into Overprescribing Response to Recommendation
TOTAL SCORE: 4
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): -1
A3 (political viability): 0
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): 0
C1 (Market readiness applicability): +1
C2 (Project readiness): 0
C3 (Move to market readiness): -1
D1 (Actionability): +1
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): 0
E (Disruptiveness): -1
F (Dividends - does the recommendation aid in social activity and inclusivity?): +1
RECOMMENDATION SUMMARY
“Medicine reviews are a core component of Comprehensive Geriatric Assessments, and if these are used more widely, with the involvement of multidisciplinary teams, the incidence of polypharmacy and the risk of adverse drug reactions should reduce. (Paragraph 80)
We recommend that the review into overprescribing — which is due to report to the Secretary of State for Health and Social Care in late 2020 — should be published as soon as possible. (Paragraph 81)”
Score
A1 (Feasibility increased by continuance of pandemic): +1
A2 (Necessity increased by covid pandemic): -1
A3 (political viability): 0
B1 (Relevance to the specific goal of increasing HALE by 5 years by 2035): 0
B2 (Relevance to general goal of biomedical healthy life extension): 0
C1 (Market readiness applicability): +1
C2 (Project readiness): 0
C3 (Move to market readiness): -1
D1 (Actionability): +1
D2 (Degree of measurability): +1
D3 (Degree of leveraging cross-sector inputs): +1
D4 (Awareness of international context): +1
D5 (Resourcefulness): +1
D6 (Reorganisation): 0
E (Disruptiveness): -1
F (Dividends - does the recommendation aid in social activity and inclusivity?): +1
RECOMMENDATION SUMMARY
“Medicine reviews are a core component of Comprehensive Geriatric Assessments, and if these are used more widely, with the involvement of multidisciplinary teams, the incidence of polypharmacy and the risk of adverse drug reactions should reduce. (Paragraph 80)
We recommend that the review into overprescribing — which is due to report to the Secretary of State for Health and Social Care in late 2020 — should be published as soon as possible. (Paragraph 81)”